A Nurse-Led Intervention for Fear of Progression in Advanced Cancer

Status Active, not recruiting

Clinical Trial Summary

This clinical trial focuses on a nurse-led program that is designed to help patients cope with worries, fears, and uncertainty about the future. The purpose of this study is to understand if the program is helpful and practical to carry out at medical centers and community clinics. This study may help patients learn more effective ways to cope and respond to your concerns and any unhelpful thoughts.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To assess the feasibility and acceptability of the revised day by day (DBD) intervention in an academic and community settings. II. To assess the preliminary effects of the revised DBD intervention for reducing fear of progression (FOP) and improving distress, anxiety, depression, metacognitions (beliefs about worry), and mindfulness. OUTLINE: Patients participate in 5 videoconference sessions over 30 minutes each over 6 weeks focused on worry management skills, values-based goal setting, and brief mindfulness-based practices, then complete patient workbook activities after each session over 15-20 minutes per day. Patients also complete a survey over 8 minutes at 6 weeks, an exit interview at 7 weeks, and questionnaires over 25 minutes each at baseline, 6 weeks, and 10 weeks. ;

Study Design

Related Conditions & MeSH terms

Advanced Lung Carcinoma
Genital Neoplasms, Female
Lung Neoplasms
Metastatic Malignant Female Reproductive System Neoplasm
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Clinical Trial Details

NCT number	NCT04819997
Study type	Interventional
Source	City of Hope Medical Center
Contact
Status	Active, not recruiting
Phase	N/A
Start date	March 8, 2021
Completion date	December 20, 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04267913` - Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)	Phase 2
Recruiting	`NCT04151940` - PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer	N/A
Terminated	`NCT03707925` - Bronchoscopic Laser Ablation of Peripheral Lung Tumors	N/A
Active, not recruiting	`NCT04081688` - Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC	Phase 1
Recruiting	`NCT04929041` - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative	Phase 2/Phase 3
Active, not recruiting	`NCT04250545` - Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer	Phase 1
Terminated	`NCT04396535` - Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04514497` - Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer	Phase 1
Withdrawn	`NCT05161533` - Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial	Phase 2
Recruiting	`NCT04919369` - All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer	Phase 1
Terminated	`NCT03662074` - Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer	Phase 2
Recruiting	`NCT04073745` - Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer	Phase 1
Withdrawn	`NCT04186988` - [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy	Early Phase 1
Active, not recruiting	`NCT03600701` - Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT03637816` - Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer	Phase 2/Phase 3
Active, not recruiting	`NCT04514484` - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Phase 1
Recruiting	`NCT05234307` - PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT06122064` - A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer	N/A
Active, not recruiting	`NCT04533451` - Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT03776253` - Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer	N/A